Farmas USA

mucho volumen en los ultimos minutos ... ya era de ver algo vida, hombre
AMRN

Estamos cerquita my friend,estamos cerquita :)

GALE

The launch of Abstral will accelerate revenue initiation to 2013 reaching cash flow positive in 18-24 months; and reduce overall company cash burn through the launch of NeuVax.

We believe NeuVax has a blockbuster potential if it reaches the market.

We believe Galena should be valued at $300 to $400 million in market cap. We have a price target of $4.50 per share for GALE which corresponds to a $375 million in market cap based on 83 million outstanding shares.

http://seekingalpha.com/article/1585992-galena-why-we-think-there-is-more-room-for-significant-share-price-appreciation?source=intbrokers_regular

BCRX

BioCryst Pharmaceuticals, Inc. (the “Company”) announced that it intends to offer shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering for a total of no more than $20 million in gross proceeds (the “Offering”).

http://boardvote.com/symbol/BCRX/communique/403499

Gracias Ana, coincido completamente con el articulista, me gusta muchísimo Galena.

Por cierto Abstral es a día de hoy el mejor tratamiento para el dolor irruptivo oncológico, eso no lo digo yo, lo dicen los oncólogos y hasta la competencia.

abstral

Pichiwillis de Abstral, debajo los coches con los que soñamos todos.

Mack

The major risk factor for MACK includes expected failure for several Phase II clinical trials for MM-121 as previously reported and updated in the recent prospectus filing. I believe this is mostly a headline risk since most of the bad news should already be reflected in stock unless the drug fails in every ongoing Phase II trial.

estoy fuera pero no porque quiera, sino porque es mejor aficionarse a jugar a los chinos que a seguir farmas, sobre todo cuando no tienes un duro. esta es de las que dará dinero, doblar estos precios seguro.
GALE

Espero que aciertes, y que estés dentro cuando pase